Tenet Healthcare
THC
$195.88
+2.19%
Tenet Healthcare Corporation is a major healthcare services organization operating a network of acute and specialty hospitals, ambulatory surgery centers, and outpatient facilities primarily across the Southern United States. The company is a significant player in the for-profit hospital industry, distinguishing itself through its dual focus on hospital operations and its Conifer Health Solutions segment, which provides revenue cycle management services to third parties. The current investor narrative is centered on the company's ability to navigate a challenging operating environment, as recent earnings reports show a divergence between strong profitability and softer-than-expected revenue, driven by an unfavorable patient insurance mix, which is a key point of debate regarding future growth sustainability.…
THC
Tenet Healthcare
$195.88
Investment Opinion: Should I buy THC Today?
Rating: Hold. The core thesis is that THC presents a compelling fundamental value proposition currently overshadowed by negative momentum and near-term growth uncertainty, making it a 'show me' story rather than an immediate buy.
Supporting evidence includes a forward P/E of 10.32x, which implies earnings growth and is historically low for the company. The company is highly profitable with a 16.46% operating margin and generates massive free cash flow ($2.53B TTM). Analyst sentiment is unanimously bullish, and the stock trades at a significant discount to its 52-week high of $247.21. However, these positives are counterbalanced by an 11.25% six-month decline, soft Q1 sales news, and high financial leverage (D/E of 3.12).
The thesis would upgrade to a Buy if the stock stabilizes above $200, confirming a break in the downtrend, and/or Q2 2026 results demonstrate a reversal of the unfavorable patient mix issue, validating the raised profit outlook. It would downgrade to a Sell if revenue growth turns negative or if the stock breaks below its 52-week low of $145.27, signaling a fundamental breakdown. Relative to its own history, the stock appears undervalued, but relative to near-term operational risks, it is fairly valued, awaiting clearer growth signals.
Sign up to view all
THC 12-Month Price Forecast
THC is a bifurcated story where deep value fundamentals clash with deteriorating technicals and near-term operational headwinds. The high cash generation and low earnings multiple create a margin of safety, but the stock needs to demonstrate it can overcome the patient mix issue to justify a re-rating. The base case of range-bound trading is most likely, as the market awaits confirmation of growth sustainability. The stance would upgrade to Bullish on a confirmed reversal of the revenue softness trend and a technical break above $215. It would downgrade to Bearish on a breakdown below the $145 support level, which would signal the value trap scenario is playing out.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Tenet Healthcare's 12-month outlook, with a consensus price target around $254.64 and implied upside of +30.0% versus the current price.
Average Target
$254.64
7 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
7
covering this stock
Price Range
$157 - $255
Analyst target range
The stock is covered by 7 analysts, and recent institutional ratings from firms like Guggenheim, Mizuho, and Barclays uniformly show 'Buy' or 'Outperform' actions, indicating a strong bullish consensus among covering firms. The consensus average target price is not explicitly provided in the analyst data block, which contains estimated EPS and revenue figures instead; therefore, the implied upside or downside to a consensus target cannot be calculated from the given data. The target price range is also not available in the provided dataset. The pattern from the institutional ratings data is unequivocally positive, with ten consecutive ratings from February to March 2026 all being Buy or Outperform actions with no downgrades, signaling strong and recent analyst conviction. The lack of explicit price targets in the data limits the precision of this analysis, but the unanimous bullish rating actions from multiple firms suggest analysts see fundamental value at current levels despite recent price weakness.
Bulls vs Bears: THC Investment Factors
The evidence presents a classic value vs. momentum conflict. The bullish case is grounded in strong fundamentals: high profitability, robust cash flow, a discounted valuation, and unanimous analyst support. The bearish case is driven by powerful technical deterioration, emerging revenue headwinds, and high leverage. Currently, the bearish momentum has the upper hand, as the stock price action reflects immediate market concerns overgrowth sustainability that outweigh the attractive fundamental metrics. The single most important tension is whether the company's operational efficiency and raised profit guidance can overcome the headwinds from an unfavorable patient mix and decelerating revenue growth. The resolution of this Q1 sales softness in upcoming reports will be the critical determinant of the thesis.
Bullish
- Strong Profitability & Raised Outlook: The company delivered a strong earnings beat and raised its full-year profit outlook, as per recent news. This is supported by a robust operating margin of 16.46% and a high return on equity of 33.34%, amplified by leverage.
- Attractive Valuation Multiples: The stock trades at a trailing P/E of 12.83x and a forward P/E of 10.32x, indicating expected earnings growth. This valuation is near the lower end of its multi-year historical range, suggesting a discount relative to its own history.
- Exceptional Cash Generation: Tenet generates substantial free cash flow, with $2.53 billion over the trailing twelve months. This strong cash flow supports a healthy current ratio of 1.76 and provides financial flexibility for debt management or strategic initiatives.
- Unanimous Analyst Bullishness: Recent institutional ratings from 7 analysts, including Guggenheim and Barclays, are uniformly 'Buy' or 'Outperform' with no downgrades. This strong consensus signals fundamental value is seen at current levels despite recent price weakness.
Bearish
- Severe Technical Downtrend: The stock is in a pronounced downtrend, down 11.25% over six months and 8.11% YTD, trading near the lower end of its 52-week range. It shows stark negative relative strength of -13.66 vs. the S&P 500 over one month, indicating company-specific selling pressure.
- Revenue Growth Concerns & Mix Issues: Recent news highlights 'soft Q1 sales' due to an unfavorable patient insurance mix, a key industry headwind. This raises questions about the sustainability of top-line growth despite the company's raised profit outlook.
- High Financial Leverage: The company carries a high debt-to-equity ratio of 3.12. While common for the sector, this leverage amplifies risks in a rising interest rate environment and contributes to the elevated ROE, which may not be purely operational.
- Elevated Short Interest: A short ratio of 2.21 indicates significant bearish speculative positioning in the market. This can exacerbate downward price moves and reflects skepticism about the stock's near-term prospects.
THC Technical Analysis
The stock is in a pronounced downtrend, having declined 11.25% over the past six months and 8.11% year-to-date as of the current date. With a current price of $183.27, the stock is trading near the lower end of its 52-week range, at approximately 74% of the distance from its 52-week low of $145.27 to its high of $247.21, indicating it is in a zone of potential value but also reflecting significant selling pressure and negative momentum. Recent short-term momentum is decisively negative, with the stock down 3.68% over the past month and 3.18% over the past three months, which contrasts sharply with the broader market's positive performance (SPY up 9.98% and 4.14% over the same periods, respectively), as evidenced by a stark relative strength of -13.66 over one month. This divergence from the market and the longer-term 1-year gain of 26.14% suggests the stock is experiencing a significant correction or trend reversal, likely driven by company-specific fundamental concerns rather than broader market weakness. Key technical support is clearly defined at the 52-week low of $145.27, while resistance sits at the recent high of $247.21; a breakdown below the $145 support would signal a major bearish continuation, while a recovery above the $200 level would be needed to suggest stabilization. The stock's volatility relative to the market is not explicitly quantified by beta in the provided data, but its significant drawdown of -27.65% and wide 52-week range point to above-average volatility, which investors must factor into risk management.
Beta
1.30
1.30x market volatility
Max Drawdown
-27.6%
Largest decline past year
52-Week Range
$147-$247
Price range past year
Annual Return
+26.7%
Cumulative gain past year
| Period | THC Return | S&P 500 |
|---|---|---|
| 1m | +0.3% | +8.6% |
| 3m | -13.5% | +6.7% |
| 6m | -0.4% | +9.8% |
| 1y | +26.7% | +26.6% |
| ytd | -1.8% | +8.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
THC Fundamental Analysis
Revenue growth has been positive but is showing signs of deceleration; the most recent quarterly revenue (Q4 2025) was $5.527 billion, representing a year-over-year growth of 8.97%, which is a healthy rate. However, examining the sequential quarterly trend from the income statements reveals revenue of $5.223B (Q1 2025), $5.271B (Q2), $5.289B (Q3), to $5.527B (Q4), indicating a relatively stable top line with a notable jump in the final quarter, though the recent news of 'soft Q1 sales' suggests this momentum may be faltering. The company is solidly profitable, with net income of $371 million in Q4 2025 and a net margin of 6.70%, supported by a gross margin of 41.52%. Profitability has been consistent, with net income figures of $406M, $288M, $342M, and $371M over the four quarters of 2025, and margins have remained stable, with the operating margin reported at 16.46% in the valuation data, indicating effective cost control. The balance sheet shows a leveraged but manageable financial structure, with a debt-to-equity ratio of 3.12, which is high but not uncommon for the capital-intensive healthcare sector. Financial health is supported by strong cash generation, with free cash flow over the trailing twelve months at $2.53 billion and a current ratio of 1.76, providing ample liquidity; the return on equity of 33.34% is exceptionally high, largely amplified by the significant financial leverage.
Quarterly Revenue
$5.5B
2025-12
Revenue YoY Growth
+0.08%
YoY Comparison
Gross Margin
+0.41%
Latest Quarter
Free Cash Flow
$2.5B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is THC Overvalued?
Given the company's consistent profitability with a positive net income, the primary valuation metric selected is the Price-to-Earnings (PE) ratio. The trailing twelve-month PE ratio is 12.83x, while the forward PE is notably lower at 10.32x, indicating the market expects earnings growth in the coming year. The gap between trailing and forward multiples suggests analysts are forecasting an increase in earnings, which aligns with the company's raised full-year profit outlook mentioned in recent news. Compared to sector averages, specific industry comparison data is not provided in the valuation data block, so a direct peer comparison cannot be quantified; however, a trailing PE of ~13x for a profitable healthcare services company with a 33% ROE does not appear excessively valued on the surface, pending sector context. Historically, the stock's own valuation has compressed significantly; the historical ratios show the PE ratio was as high as 44.94x in Q1 2021 and has fluctuated widely, but the current trailing PE of 12.83x is near the lower end of its multi-year historical range (based on provided data points from 2021-2025), suggesting the stock is trading at a relatively discounted level compared to its own history, which may reflect market concerns over growth sustainability or sector headwinds.
PE
12.7x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 1x~37x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
6.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks center on the company's leveraged balance sheet, with a debt-to-equity ratio of 3.12, which increases interest expense sensitivity and refinancing risk. While strong free cash flow of $2.53B provides a cushion, a sustained period of softer revenue growth, as hinted at with 'soft Q1 sales,' could pressure cash flow coverage of debt. Furthermore, the high Return on Equity of 33.34% is significantly amplified by this leverage, masking underlying operational returns and creating vulnerability if earnings decline.
Market & Competitive Risks include valuation compression, as the stock trades at a forward P/E of 10.32x, which, while low historically, could re-rate lower if growth concerns persist. The stock exhibits high idiosyncratic risk, evidenced by its -27.65% max drawdown and severe underperformance relative to the market (SPY +9.98% vs. THC -3.68% over one month). Regulatory changes in healthcare reimbursement and intense competition for patients in its core Southern U.S. markets pose persistent external threats to pricing and volume.
The Worst-Case Scenario involves a continuation of the unfavorable patient insurance mix leading to consecutive revenue misses, triggering analyst downgrades from their currently bullish stance. This could combine with a broader market downturn, forcing a re-rating to a lower multiple. The realistic downside is anchored by the 52-week low of $145.27, which represents a potential loss of approximately -21% from the current price of $183.27. A break below this support could lead to further declines towards the $130-$140 range, representing a total loss of -25% to -30%.
FAQ
The key risks are, in order of severity: 1) Operational: Sustained unfavorable patient insurance mix pressuring revenue growth, as recently reported. 2) Financial: High debt burden (D/E 3.12) increasing interest expense risk and amplifying earnings volatility. 3) Market/Sentiment: Continued negative momentum and high short interest (ratio 2.21) exacerbating downward moves. 4) Macro: Sensitivity to healthcare reimbursement policies and broader economic cycles affecting patient volumes. The combination of leverage and revenue uncertainty presents the most acute near-term risk.
The 12-month outlook presents three scenarios. The Base Case (50% probability) sees the stock trading between $190 and $220 as growth concerns balance against low valuation, representing modest upside from $183. The Bull Case (30% probability) targets $240-$260 if operational execution improves, driving multiple expansion. The Bear Case (20% probability) risks a decline to the $145-$170 range if revenue weakness persists. The most likely outcome is the Base Case, predicated on the assumption that the company manages, but does not spectacularly resolve, its current headwinds while maintaining profitability.
Based on its own history and profitability metrics, THC appears undervalued. Its trailing P/E of 12.83x and forward P/E of 10.32x are near the lower end of its multi-year range. The market is applying a significant discount, pricing in concerns over revenue growth sustainability and the company's high leverage (D/E of 3.12). Compared to simply earnings and cash flow, the stock is cheap, but the valuation implies the market expects muted growth or potential earnings degradation. It is fairly valued to slightly undervalued when weighing strong fundamentals against clear operational risks.
THC is a complex buy at current levels. For value investors focused on fundamentals, it presents a strong case with a forward P/E of 10.32x, robust free cash flow of $2.53B, and unanimous bullish analyst ratings. However, the significant price downtrend (-11.25% over 6 months) and emerging revenue headwinds make it a higher-risk proposition. It could be a good buy for patient investors willing to wait for operational execution to overcome near-term challenges, but it is not suitable for low-risk or short-term portfolios. The key is believing the company's profit outlook over the market's current growth concerns.
THC is more suitable for a medium to long-term investment horizon (2+ years). Its high volatility, evidenced by a -27.65% max drawdown, and current downtrend make it a poor candidate for short-term trading. A longer horizon allows time for the company's operational strategy to address revenue mix issues, for its strong cash flow to reduce leverage, and for the valuation discount to potentially close. The stock does not pay a dividend, so the total return is dependent on capital appreciation driven by earnings growth and multiple re-rating, processes that typically require multiple quarters to unfold.